Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations

Ten-Year Survival in Patients With BRCA1-Negative and BRCA1-Positive Breast Cancer

(2013) Tomasz Huzarski et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality

(2010) Susan M. Domchek   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers

(2009) T. R. Rebbeck et al.   JNCI-Journal of the National Cancer Institute

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

(2009) Kathy S Albain et al.   LANCET ONCOLOGY

The Average Cumulative Risks of Breast and Ovarian Cancer for Carriers of Mutations in BRCA1 and BRCA2 Attending Genetic Counseling Units in Spain

(2008) R. L. Milne et al.   CLINICAL CANCER RESEARCH

Prognostic Utility of the 21-Gene Assay in Hormone Receptor–Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features

(2008) Lori J. Goldstein et al.   JOURNAL OF CLINICAL ONCOLOGY